pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › MRNA

MRNA PDUFA Date: mRNA-1010

FDA decision (PDUFA) target 2026-08-05 · Moderna Inc. · Seasonal influenza in U.S. adults 50 years of age and older

MRNA run-up into the PDUFA (last ~120 days)

$61.8$45.37
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-08-05
Drug / candidatemRNA-1010
IndicationSeasonal influenza in U.S. adults 50 years of age and older
CompanyModerna Inc.
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNCT05415462 · completed

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the MRNA PDUFA date?
The FDA PDUFA target date for MRNA (Moderna Inc.) is 2026-08-05 for mRNA-1010. Dates are company/FDA-sourced and can slip — verify against primary filings.
What is MRNA's drug mRNA-1010?
mRNA-1010 is Moderna Inc.'s candidate under FDA review for Seasonal influenza in U.S. adults 50 years of age and older.
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.